Undecimal Bio 🇮🇱
Seed · €16M
Targeted RNA medicines for diseases beyond the liver.
About Undecimal Bio
Undecimal Bio is developing a platform for delivering RNA therapeutics, using combinatorial chemistry and artificial intelligence to design delivery approaches for multiple disease indications.
Undecimal Bio is a Israel-based company founded in 2025, now around 12 people. It has raised $18.9M in disclosed funding. FundFinder classes it as Health & Bio.
Its investors also appear on FundFinder's most-active lists for Seed · DeepTech (80 funds), Seed · B2B (120 funds), Seed · Fintech (111 funds).
Company facts from Harmonic and public filings; team backgrounds from public profiles. Refreshed weekly.
Want the latest on Undecimal Bio? Our research agent pulls the current
description, latest round and full investor base from public sources (about a minute).
Seed · €16M · Oct 2026
- Entree Capital — Entrée Capital is a multi-stage VC firm with offices in Tel Aviv, London and New York. · cheques £1M – £10M
- IQ Capital — IQ Capital is a deep-tech early stage VC investing in companies capable of dominating global markets, focused on breakthrough technologies in computer science, energy, life sciences, fintech, space, and advanced enginee · cheques £500k – £10M